An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
Eosinophils play a key role in the pathogenesis of eosinophilic oesophagitis. Therapies that
suppress eosinophil recruitment and activation may give a benefit. Mepolizumab is a humanised
monoclonal antibody against interleukin-5 (IL-5). This study will evaluate the ability of
mepolizumab to decrease the recruitment and infiltration of eosinophils into the oesophagus,
thereby reducing the inflammation and symptoms of EE (eosinophilic oesophagitis) in adult
patients.